Postoperative acute pain after bariatric surgery
Conditions
Interventions
Sufentanil Group (Group S):Postoperative PCA was performed with sufentanil at a loading dose of 3 ug and PCA bolus dose of 1 ug per press.
Oxycodone Group (Group O):Postoperative PCA was performed with oxycodone at a loading dose of 3 mg and PCA bolus dose of 1 mg per press.
Low-dose Tegileridine Group (Group LT):Postoperative PCA was performed with tegileridine at a loading dose of 0.75 mg and PCA bolus dose of 0.05 mg per press.
High-dose Tegileridine Group (Group HT):Postoperative PCA was performed with tegileridine at a loading dose of 0.75 mg and PCA bolus dose of 0.1 mg per press.
Sponsors
Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Inpatients aged 18 to 65 years, regardless of gender; (1) Patients scheduled for elective bariatric surgery under general anesthesia, with an estimated surgical duration of 152 cm and a body mass index (BMI) >=28 kg/m^2; 4. Participants who fully understand the purpose, content, procedures, and risks of this trial, and voluntarily agree to participate in the clinical trial by signing the informed consent form;
Exclusion criteria
Exclusion criteria: 1.Significant preoperative psychiatric disorders or long-term use of psychotropic medications; 2.Dependence on opioid analgesics or other pain medications; 3.Use of any analgesic medications within 24 hours before surgery, including nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, pregabalin, etc. 4.Concomitant use of nerve block anesthesia, including transversus abdominis plane block, etc; 5.High risk of difficult airway: actual body weight > 175% of ideal body weight, or significant symptoms of obstructive sleep apnea, or Mallampati airway classification Grade IV; 6.Oesity Surgery Mortality Risk Score > 3 points; 7.Known hypersensitivity or contraindication to any drug used in the anesthesia regimen; 8.Pregnancy, lactation or planned pregnancy;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient-controlled analgesia status; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain intensity;Rescue analgesia status;resting summed pain intensity difference over 24?hours (rSPID24);Recovery status;General Observation Indicators;Adverse reaction status; | — |
Countries
China
Contacts
Public ContactJin Wenjie
Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
Outcome results
None listed